{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:53:08Z","timestamp":1794016388622,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2025JJ50487"],"award-info":[{"award-number":["2025JJ50487"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2025JJ80840"],"award-info":[{"award-number":["2025JJ80840"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571530"],"award-info":[{"award-number":["82571530"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273219"],"award-info":[{"award-number":["82273219"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69339-7","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:22:56Z","timestamp":1770668576000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CD38 degrades MAVS through mitophagy to inhibit type I interferon secretion in nasopharyngeal carcinoma cells and impairs CD8+T cell-mediated anti-tumor immunity"],"prefix":"10.1038","volume":"17","author":[{"given":"Lin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-1528","authenticated-orcid":false,"given":"Feng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3224-6803","authenticated-orcid":false,"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-4439","authenticated-orcid":false,"given":"Yanhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"69339_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"69339_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma, B. B. Y. et al. Antitumor activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 Consortium (NCI-9742). J. Clin. Oncol. 36, 1412\u20131418 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69339_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00558-1","volume":"8","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma. NPJ Precis. Oncol. 8, 65 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"69339_CR4","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","volume":"77","author":"A Prat","year":"2017","unstructured":"Prat, A. et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 77, 3540\u20133550 (2017).","journal-title":"Cancer Res."},{"key":"69339_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s40425-019-0752-4","volume":"7","author":"YQ Wang","year":"2019","unstructured":"Wang, Y. Q. et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J. Immunother. Cancer 7, 298 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"69339_CR6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"key":"69339_CR7","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 Study. J. Clin. Oncol. 35, 4050\u20134056 (2017).","journal-title":"J. Clin. Oncol."},{"key":"69339_CR8","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.oraloncology.2020.105127","volume":"113","author":"D Johnson","year":"2021","unstructured":"Johnson, D. & Ma, B. B. Y. Targeting the PD-1\/ PD-L1 interaction in nasopharyngeal carcinoma. Oral. Oncol. 113, 105127 (2021).","journal-title":"Oral. Oncol."},{"key":"69339_CR9","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen, L. et al. Gibbons, CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 Blockade. Cancer Discov. 8, 1156\u20131175 (2018).","journal-title":"Cancer Discov."},{"key":"69339_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","volume":"10","author":"KA Hogan","year":"2019","unstructured":"Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front. Immunol. 10, 1187 (2019).","journal-title":"Front. Immunol."},{"key":"69339_CR11","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1002\/jcp.30760","volume":"237","author":"F Zeng","year":"2022","unstructured":"Zeng, F. et al. Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases. J. Cell Physiol. 237, 2796\u20132807 (2022).","journal-title":"J. Cell Physiol."},{"key":"69339_CR12","doi-asserted-by":"publisher","first-page":"775649","DOI":"10.3389\/fonc.2022.775649","volume":"12","author":"W Li","year":"2022","unstructured":"Li, W. et al. CD38: a significant regulator of macrophage function. Front. Oncol. 12, 775649 (2022).","journal-title":"Front. Oncol."},{"key":"69339_CR13","doi-asserted-by":"publisher","first-page":"113395","DOI":"10.1016\/j.biopha.2022.113395","volume":"153","author":"W Li","year":"2022","unstructured":"Li, W., Liang, L., Liao, Q., Li, Y. & Zhou, Y. CD38: an important regulator of T cell function. Biomed. Pharmacother. 153, 113395 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"69339_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17\u201335 (2020).","journal-title":"Immunity"},{"key":"69339_CR15","doi-asserted-by":"publisher","first-page":"105514","DOI":"10.1016\/j.phrs.2021.105514","volume":"166","author":"SS Zou","year":"2021","unstructured":"Zou, S. S. et al. Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: how therapy can overcome them. Pharm. Res. 166, 105514 (2021).","journal-title":"Pharm. Res."},{"key":"69339_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2159-8290.CD-23-0486","volume":"14","author":"T Murayama","year":"2024","unstructured":"Murayama, T. et al. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in small cell lung cancer. Cancer Discov. 14, 468\u2013491 (2024).","journal-title":"Cancer Discov."},{"key":"69339_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng, W. et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174, 549\u2013563.e19 (2018).","journal-title":"Cell"},{"key":"69339_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-23-0700","volume":"14","author":"T Tani","year":"2024","unstructured":"Tani, T. et al. TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes antitumor immunity. Cancer Discov. 14, 752\u2013765 (2024).","journal-title":"Cancer Discov."},{"key":"69339_CR19","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).","journal-title":"Sci. Transl. Med."},{"key":"69339_CR20","doi-asserted-by":"publisher","first-page":"568931","DOI":"10.3389\/fimmu.2020.568931","volume":"11","author":"K Hudson","year":"2020","unstructured":"Hudson, K., Cross, N., Jordan-Mahy, N. & Leyland, R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front. Immunol. 11, 568931 (2020).","journal-title":"Front. Immunol."},{"key":"69339_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.tcb.2019.09.004","volume":"29","author":"JW Yewdell","year":"2019","unstructured":"Yewdell, J. W., Dersh, D. & Fahraeus, R. Peptide channeling: the key to MHC class I immunosurveillance?. Trends Cell Biol. 29, 929\u2013939 (2019).","journal-title":"Trends Cell Biol."},{"key":"69339_CR22","doi-asserted-by":"crossref","unstructured":"Zhang, B. et al. Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation. J. Immunother. Cancer 11, e005592 (2023).","DOI":"10.1136\/jitc-2022-005592"},{"key":"69339_CR23","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-22-3382","volume":"83","author":"I Mondal","year":"2023","unstructured":"Mondal, I. et al. PP2Ac deficiency enhances tumor immunogenicity by activating sting-type i interferon signaling in glioblastoma. Cancer Res. 83, 2527\u20132542 (2023).","journal-title":"Cancer Res."},{"key":"69339_CR24","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1016\/j.molcel.2023.10.043","volume":"83","author":"G Zhang","year":"2023","unstructured":"Zhang, G. et al. CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. Mol. Cell 83, 4370\u20134385.e9 (2023).","journal-title":"Mol. Cell"},{"key":"69339_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"69339_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol. Life Sci. 79, 191 (2022).","journal-title":"Cell Mol. Life Sci."},{"key":"69339_CR27","doi-asserted-by":"publisher","first-page":"1399926","DOI":"10.3389\/fimmu.2024.1399926","volume":"15","author":"M Huang","year":"2024","unstructured":"Huang, M. et al. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies. Front. Immunol. 15, 1399926 (2024).","journal-title":"Front. Immunol."},{"key":"69339_CR28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","volume":"24","author":"I Canadas","year":"2018","unstructured":"Canadas, I. et al. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat. Med. 24, 1143\u20131150 (2018).","journal-title":"Nat. Med."},{"key":"69339_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","volume":"88","author":"F Malavasi","year":"2008","unstructured":"Malavasi, F. et al. Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology. Physiol. Rev. 88, 841\u2013886 (2008).","journal-title":"Physiol. Rev."},{"key":"69339_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/138161209787185788","volume":"15","author":"EN Chini","year":"2009","unstructured":"Chini, E. N. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr. Pharm. Des. 15, 57\u201363 (2009).","journal-title":"Curr. Pharm. Des."},{"key":"69339_CR31","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818\u2013822 (2019).","journal-title":"Science"},{"key":"69339_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11164-2","volume":"10","author":"MT Vo","year":"2019","unstructured":"Vo, M. T., Smith, B. J., Nicholas, J. & Choi, Y. B. Activation of NIX-mediated mitophagy by an interferon regulatory factor homologue of human herpesvirus. Nat. Commun. 10, 3203 (2019).","journal-title":"Nat. Commun."},{"key":"69339_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cell.2016.11.042","volume":"168","author":"Y Wei","year":"2017","unstructured":"Wei, Y., Chiang, W. C., Sumpter, R. Jr., Mishra, P. & Levine, B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell 168, 224\u2013238.e10 (2017).","journal-title":"Cell"},{"key":"69339_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/cr.2017.23","volume":"27","author":"V Lahiri","year":"2017","unstructured":"Lahiri, V. & Klionsky, D. J. PHB2\/prohibitin 2: an inner membrane mitophagy receptor. Cell Res. 27, 311\u2013312 (2017).","journal-title":"Cell Res."},{"key":"69339_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/15548627.2019.1628520","volume":"16","author":"C Yan","year":"2020","unstructured":"Yan, C. et al. PHB2 (prohibitin 2) promotes PINK1-PRKN\/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. Autophagy 16, 419\u2013434 (2020).","journal-title":"Autophagy"},{"key":"69339_CR36","doi-asserted-by":"publisher","first-page":"1371878","DOI":"10.3389\/fonc.2024.1371878","volume":"14","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with a 5-year follow-up. Front. Oncol. 14, 1371878 (2024).","journal-title":"Front. Oncol."},{"key":"69339_CR37","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s00330-023-09987-1","volume":"34","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. A contrast-enhanced CT radiomics-based model to identify candidates for deintensified chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients. Eur. Radiol. 34, 1302\u20131313 (2024).","journal-title":"Eur. Radiol."},{"key":"69339_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10494-7","volume":"23","author":"GD Jia","year":"2023","unstructured":"Jia, G. D. et al. Clinical characteristics and prognostic factors affecting survival after radical radiotherapy for early and late post-treatment metastatic nasopharyngeal carcinoma. BMC Cancer 23, 7 (2023).","journal-title":"BMC Cancer"},{"key":"69339_CR39","doi-asserted-by":"crossref","unstructured":"Huang, H. et al. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). Int. J. Oncol. 63, 97 (2023).","DOI":"10.3892\/ijo.2023.5545"},{"key":"69339_CR40","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00432-022-04214-8","volume":"149","author":"S Wang","year":"2023","unstructured":"Wang, S., Chen, S., Zhong, Q. & Liu, Y. Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era. J. Cancer Res. Clin. Oncol. 149, 2071\u20132079 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"69339_CR41","first-page":"585","volume":"54","author":"Y Ge","year":"2019","unstructured":"Ge, Y. et al. CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells. Int. J. Oncol. 54, 585\u2013599 (2019).","journal-title":"Int. J. Oncol."},{"key":"69339_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/mc.22279","volume":"55","author":"D Zheng","year":"2016","unstructured":"Zheng, D. et al. CD38 is a putative functional marker for side population cells in human nasopharyngeal carcinoma cell lines. Mol. Carcinog. 55, 300\u2013311 (2016).","journal-title":"Mol. Carcinog."},{"key":"69339_CR43","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1080\/10428194.2022.2090551","volume":"63","author":"A Paulus","year":"2022","unstructured":"Paulus, A., Malavasi, F. & Chanan-Khan, A. CD38 as a multifaceted immunotherapeutic target in CLL. Leuk. Lymphoma 63, 2265\u20132275 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"69339_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3892\/ol.2015.3218","volume":"10","author":"D Zheng","year":"2015","unstructured":"Zheng, D. et al. Dysregulation of the PI3K\/Akt signaling pathway affects cell cycle and apoptosis of side population cells in nasopharyngeal carcinoma. Oncol. Lett. 10, 182\u2013188 (2015).","journal-title":"Oncol. Lett."},{"key":"69339_CR45","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/mc.22677","volume":"56","author":"S Liao","year":"2017","unstructured":"Liao, S. et al. CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions. Mol. Carcinog. 56, 2245\u20132257 (2017).","journal-title":"Mol. Carcinog."},{"key":"69339_CR46","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.3892\/or.2014.3537","volume":"32","author":"S Liao","year":"2014","unstructured":"Liao, S. et al. CD38 is highly expressed and affects the PI3K\/Akt signaling pathway in cervical cancer. Oncol. Rep. 32, 2703\u20132709 (2014).","journal-title":"Oncol. Rep."},{"key":"69339_CR47","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1158\/2159-8290.CD-18-0798","volume":"8","author":"D Mittal","year":"2018","unstructured":"Mittal, D., Vijayan, D. & Smyth, M. J. Overcoming acquired PD-1\/PD-L1 resistance with CD38 Blockade. Cancer Discov. 8, 1066\u20131068 (2018).","journal-title":"Cancer Discov."},{"key":"69339_CR48","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao, L. L. & Kagan, J. C. Targeting innate immune pathways for cancer immunotherapy. Immunity 56, 2206\u20132217 (2023).","journal-title":"Immunity"},{"key":"69339_CR49","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41590-021-00896-3","volume":"22","author":"M Takahashi","year":"2021","unstructured":"Takahashi, M. et al. The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-beta pathway. Nat. Immunol. 22, 485\u2013496 (2021).","journal-title":"Nat. Immunol."},{"key":"69339_CR50","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1158\/0008-5472.CAN-23-1082","volume":"84","author":"H Tao","year":"2024","unstructured":"Tao, H. et al. PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma. Cancer Res. 84, 419\u2013433 (2024).","journal-title":"Cancer Res."},{"key":"69339_CR51","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1158\/2159-8290.CD-23-0007","volume":"13","author":"AA Guirguis","year":"2023","unstructured":"Guirguis, A. A. et al. Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances antitumor immunity. Cancer Discov. 13, 2228\u20132247 (2023).","journal-title":"Cancer Discov."},{"key":"69339_CR52","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang, W. et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 5, 12189\u201312202 (2014).","journal-title":"Oncotarget"},{"key":"69339_CR53","doi-asserted-by":"publisher","first-page":"122371","DOI":"10.1016\/j.lfs.2023.122371","volume":"338","author":"B Zhang","year":"2024","unstructured":"Zhang, B., Li, W., Cao, J., Zhou, Y. & Yuan, X. Prohibitin 2: a key regulator of cell function. Life Sci. 338, 122371 (2024).","journal-title":"Life Sci."},{"key":"69339_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.molcel.2017.09.005","volume":"68","author":"S Jin","year":"2017","unstructured":"Jin, S. et al. Tetherin suppresses type I interferon signaling by targeting MAVS for NDP52-mediated selective autophagic degradation in human cells. Mol. Cell 68, 308\u2013322.e4 (2017).","journal-title":"Mol. Cell"},{"key":"69339_CR55","doi-asserted-by":"publisher","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","volume":"11","author":"ZL Piedra-Quintero","year":"2020","unstructured":"Piedra-Quintero, Z. L., Wilson, Z., Nava, P. & Guerau-de-Arellano, M. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front. Immunol. 11, 597959 (2020).","journal-title":"Front. Immunol."},{"key":"69339_CR56","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cmet.2018.03.016","volume":"27","author":"MG Tarrago","year":"2018","unstructured":"Tarrago, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD(+) decline. Cell Metab. 27, 1081\u20131095.e10 (2018).","journal-title":"Cell Metab."},{"key":"69339_CR57","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1039\/c0ob00768d","volume":"9","author":"M Dong","year":"2011","unstructured":"Dong, M. et al. Design, synthesis and biological characterization of novel inhibitors of CD38. Org. Biomol. Chem. 9, 3246\u20133257 (2011).","journal-title":"Org. Biomol. Chem."},{"key":"69339_CR58","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1016\/j.bmcl.2011.05.022","volume":"21","author":"E Kellenberger","year":"2011","unstructured":"Kellenberger, E., Kuhn, I., Schuber, F. & Muller-Steffner, H. Flavonoids as inhibitors of human CD38. Bioorg. Med. Chem. Lett. 21, 3939\u20133942 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"69339_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101400","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep. Med. 5, 101400 (2024).","journal-title":"Cell Rep. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69339-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:01:59Z","timestamp":1773878519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69339"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69339-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2544"}}